Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 27, 2015, Pages 8379-8384

  Kuebler, Peter J ^a   Mehrotra, Megha L ^b   McConnell, J Jeff ^b   Holditch, Sara J ^a   Shaw, Brian I ^a   Tarosso, Leandro F ^c   Leadabrand, Kaitlyn S ^a   Milush, Jeffrey M ^a   York, Vanessa A ^a   Raposo, Rui André Saraiva ^a,d   Cheng, Rex G ^a   Eriksson, Emily M ^d   McMahan, Vanessa ^b   Glidden, David V ^e   Shiboski, Stephen ^e   Grant, Robert M ^b,f   Nixona, Douglas F ^a,d   Kallás, Esper G ^c   Gallo, Robert C ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Gladstone Institutes of Virology and Immunology   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Designated HIV 1 exposed seronegative; HIV 1; Preexposure chemoprophylaxis; T cell; Vaccine

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GAG PROTEIN; GAMMA INTERFERON; INTEGRASE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ADULT; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; METABOLISM; MONONUCLEAR CELL; MULTIVARIATE ANALYSIS; PHYSIOLOGY; STATISTICAL MODEL; VIROLOGY; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; YOUNG ADULT;

EID: 84936863056     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1501443112     Document Type: Article

References (42)

1. Clerici M, et al. (1992) Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 165(6):1012-1019.
2. Erickson AL, et al. (2008) Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level. Clin Vaccine Immunol 15(11):1745-1748.
3. Fowke KR, et al. (2000) HIV-1-specific cellular immune responses among HIV-1-resistant sex workers. Immunol Cell Biol 78(6):586-595.
4. Kebba A, et al. (2004) Distinct patterns of peripheral HIV-1-specific interferon- gamma responses in exposed HIV-1-seronegative individuals. J Infect Dis 189(9):1705-1713.
5. Kuhn L, et al. (2001) T-helper cell responses to HIV envelope peptides in cord blood: Protection against intrapartum and breast-feeding transmission. AIDS 15(1):1-9.
6. Legrand FA, et al. (2006) Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS ONE 1:e102.
7. Rowland-Jones SL, et al. (1998) Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 102(9):1758-1765.
8. Rowland-Jones SL, et al. (1993) HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 341(8849):860-861.
9. Holditch SJ, et al. (2011) Decay kinetics of HIV-1 specific T cell responses in vertically HIV-1 exposed seronegative infants. Front Immunol 2:94.
10. Shacklett BL, et al. (2002) Dendritic cell amplification of HIV type 1-specific CD8+ T cell responses in exposed, seronegative heterosexual women. AIDS Res Hum Retroviruses 18(11):805-815.
11. Kaul R, et al. (2000) HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 164(3):1602-1611.
12. Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM (2013) Virus-specific CD4(+) memoryphenotype T cells are abundant in unexposed adults. Immunity 38(2):373-383.
13. Trama AM, et al. (2014) HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe 16(2):215-226.
14. Kaul R, et al. (2001) Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest 107(3):341-349.
15. Young JM, Turpin JA, Musib R, Sharma OK (2011) Outcomes of a National Institute of Allergy and Infectious Diseases Workshop on understanding HIV-exposed but seronegative individuals. AIDS Res Hum Retroviruses 27(7):737-743.
16. Addo MM, et al. (2011) Lack of detectable HIV-1-specific CD8(+) T cell responses in Zambian HIV-1-exposed seronegative partners of HIV-1-positive individuals. J Infect Dis 203(2):258-262.
17. Hladik F, et al. (2003) Most highly exposed seronegative men lack HIV-1-specific, IFNgamma- secreting T cells. J Immunol 171(5):2671-2683.
18. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG (2007) A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 196(9):1304-1312.
19. Haynes BF, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366(14):1275-1286.
20. Plotkin SA, Gilbert PB (2012) Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 54(11):1615-1617.
21. Lederman MM, et al. (2010) Determinants of protection among HIV-exposed seronegative persons: An overview. J Infect Dis 202(Suppl 3):S333-S338.
22. Grant RM, et al.; iPrEx Study Team (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363(27):2587-2599.
23. Kaul R, et al. (2004) HIV-1 Env-specific cytotoxic T-lymphocyte responses in exposed, uninfected Kenyan sex workers: A prospective analysis. AIDS 18(15):2087-2089.
24. Pattacini L, et al.; Partners PrEP Study Team (2015) Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. J Infect Dis 211(12):1943-1952.
25. Heller T, et al. (2013) Occupational exposure to hepatitis C virus: Early T-cell responses in the absence of seroconversion in a longitudinal cohort study. J Infect Dis 208(6): 1020-1025.
26. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258(5090): 1938-1941.
27. Mori K, et al. (2001) Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: Robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain. J Virol 75(9):4023-4028.
28. Hansen SG, et al. (2013) Immune clearance of highly pathogenic SIV infection. Nature 502(7469):100-104.
29. Gray GE, et al.; HVTN 503/Phambili study team (2011) Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 11(7):507-515.
30. Priddy FH, et al.; Merck V520-016 Study Group (2008) Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46(11):1769-1781.
31. Buchbinder SP, et al.; Step Study Protocol Team (2008) Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653):1881-1893.
32. Betts MR, et al. (2005) Characterization of functional and phenotypic changes in anti- Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci USA 102(12):4512-4517.
33. Hertz T, et al. (2013) HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog 9(6): E1003404.
34. Kaul R, et al. (2001) CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 107(10):1303-1310.
35. Hansen SG, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15(3):293-299.
36. Hansen SG, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473(7348):523-527.
37. Mudd PA, et al. (2012) Escape from CD8(+) T cell responses in Mamu-B∗00801(+) macaques differentiates progressors from elite controllers. J Immunol 188(7):3364-3370.
38. Martins MA, et al. (2010) T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol 84(9):4352-4365.
39. Tarosso LF, et al. (2010) Unexpected diversity of cellular immune responses against Nef and Vif in HIV-1-infected patients who spontaneously control viral replication. PLoS ONE 5(7):e11436.
40. Goila-Gaur R, Strebel K (2008) HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5:51.
41. Refsland EW, et al. (2014) Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet 10(11):e1004761.
42. Ritchie AJ, et al. (2011) Differences in HIV-specific T cell responses between HIVexposed and -unexposed HIV-seronegative individuals. J Virol 85(7):3507-3516.